Q2 2022 Earnings Estimate for Heron Therapeutics, Inc. (NASDAQ:HRTX) Issued By Jefferies Financial Group

Heron Therapeutics, Inc. (NASDAQ:HRTXGet Rating) – Investment analysts at Jefferies Financial Group reduced their Q2 2022 earnings per share (EPS) estimates for shares of Heron Therapeutics in a note issued to investors on Monday, May 9th. Jefferies Financial Group analyst K. Shi now expects that the biotechnology company will post earnings of ($0.36) per share for the quarter, down from their previous forecast of ($0.22). Jefferies Financial Group also issued estimates for Heron Therapeutics’ Q3 2022 earnings at ($0.32) EPS, Q4 2022 earnings at ($0.26) EPS, FY2022 earnings at ($1.57) EPS, FY2023 earnings at ($1.01) EPS, FY2024 earnings at ($0.19) EPS, FY2025 earnings at $0.50 EPS and FY2026 earnings at $0.85 EPS.

Heron Therapeutics (NASDAQ:HRTXGet Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.18). Heron Therapeutics had a negative return on equity of 243.85% and a negative net margin of 258.35%. The firm had revenue of $23.46 million during the quarter, compared to the consensus estimate of $22.61 million. During the same period in the prior year, the firm posted ($0.58) EPS. The firm’s quarterly revenue was up 17.2% on a year-over-year basis.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald dropped their price objective on Heron Therapeutics from $20.00 to $12.00 in a research note on Tuesday. Cowen decreased their target price on Heron Therapeutics from $13.00 to $7.50 in a report on Tuesday. Zacks Investment Research cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 9th. Cowen decreased their target price on Heron Therapeutics from $13.00 to $7.50 in a report on Tuesday. Finally, Needham & Company LLC decreased their target price on Heron Therapeutics from $24.00 to $16.00 in a report on Tuesday, March 1st.

HRTX opened at $3.59 on Thursday. Heron Therapeutics has a one year low of $3.12 and a one year high of $16.63. The company has a debt-to-equity ratio of 6.22, a quick ratio of 2.90 and a current ratio of 2.39. The stock’s fifty day moving average is $5.19 and its 200-day moving average is $7.77. The company has a market capitalization of $367.90 million, a PE ratio of -1.56 and a beta of 1.37.

Several hedge funds have recently modified their holdings of HRTX. M&T Bank Corp grew its stake in Heron Therapeutics by 5.8% in the fourth quarter. M&T Bank Corp now owns 22,788 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 1,243 shares in the last quarter. LPL Financial LLC grew its stake in Heron Therapeutics by 8.7% in the fourth quarter. LPL Financial LLC now owns 16,250 shares of the biotechnology company’s stock valued at $148,000 after purchasing an additional 1,307 shares in the last quarter. Principal Financial Group Inc. grew its stake in Heron Therapeutics by 4.6% in the third quarter. Principal Financial Group Inc. now owns 37,534 shares of the biotechnology company’s stock valued at $401,000 after purchasing an additional 1,663 shares in the last quarter. California State Teachers Retirement System grew its stake in Heron Therapeutics by 1.3% in the third quarter. California State Teachers Retirement System now owns 129,071 shares of the biotechnology company’s stock valued at $1,380,000 after purchasing an additional 1,677 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in Heron Therapeutics by 23.0% in the third quarter. Teacher Retirement System of Texas now owns 13,983 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 2,617 shares in the last quarter.

Heron Therapeutics Company Profile (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Articles

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.